Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

Product › Details

omecamtiv mecarbil

	Next higher product group	cardiovascular drug_o
	Status	2013-07-09 development p2 existent
	Organisation	Amgen Inc. (Nasdaq: AMGN)
	Group	Amgen (Group)
	Organisation 2	Cytokinetics Inc. (Nasdaq: CYTK)

Record changed: 2020-12-25

Picture [iito] Plain Stupid Simple 650x80px

More documents for cardiovascular drug_o

[1] Cytokinetics, Inc.. (12/23/20). "Press Release: Cytokinetics Regains European Rights to Omecamtiv Mecarbil". South San Francisco, CA....
[2] Cytokinetics, Inc.. (11/23/20). "Press Release: Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 from Amgen". South San Francisco, CA....
[3] Exscientia Ltd.. (11/10/20). "Press Release: Exscientia Recruits Industry Innovator Garry Pairaudeau as Chief Technology Officer"....
[4] Novo Nordisk A/S. (6/11/20). "Press Release: Novo Nordisk to Acquire Corvidia Therapeutics and Expand Presence in Cardiovascular Disease". Bagsvaerd....
[5] Novartis AG. (1/6/20). "Press Release: Novartis Completes Tender Offer for All Outstanding Shares of The Medicines Company". Basel....
[6] Novartis AG. (1/6/20). "Press Release: Novartis Successfully Completes Acquisition of The Medicines Company, Adding a Potentially First-in-Class, Investigational Cholesterol-lowering Therapy Inclisiran". Basel....
[7] Novartis AG. (11/24/19). "Press Release: Novartis to Acquire The Medicines Company for USD 9.7 bn". Basel....
[8] MyoKardia, Inc.. (7/18/19). "Press Release: MyoKardia Announces HCM Program Updates". South San Francisco, CA....
[9] Laboratoris Sanifit S.L.. (6/26/19). "Press Release: Sanifit Announces €72.2M ($80.9M) Financing in Spain’s Largest Private Biotech Fundraise". Palma & San Diego, CA....
[10] Cerenis Therapeutics S.A.. (1/24/19). "Press Release: 2018 Annual Results and Clinical Update". Toulouse & Lakeland, US....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]